STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGEN
  4. [Form 4] REPLIGEN CORP Insider Trading Activity

Repligen (RGEN) director granted RSUs and options in Form 4 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corporation director Martin D. Madaus reported equity awards, not open-market trades. He received 995 restricted stock units, each representing one share of common stock. These units vest on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and settlement has been deferred until after his board service ends.

He was also granted stock options on 2,239 shares at an exercise price of $103.38 per share, vesting on the same schedule and expiring on May 14, 2036. Following these awards, he directly holds 6,581 common shares and indirectly holds additional shares through a spouse trust with 11 shares and a 2011 revocable trust with 1,800 shares.

Positive

  • None.

Negative

  • None.
Insider Madaus Martin D
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,239 $0.00 --
Grant/Award Common Stock 995 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 2,239 shares (Direct, null); Common Stock — 6,581 shares (Direct, null); Common Stock — 1,800 shares (Indirect, By Martin D. Madaus 2011 Revocable Trust)
Footnotes (1)
  1. Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Restricted stock units granted 995 units Award to director; each unit equals one common share
Stock options granted 2,239 options Right to buy Repligen common stock
Option exercise price $103.38 per share Stock option grant on May 14, 2026
Option expiration date May 14, 2036 Final date to exercise options if vested
Direct shares after transaction 6,581 shares Common stock directly owned by Madaus
Indirect spouse trust holdings 11 shares Common stock held via spouse trust
Indirect revocable trust holdings 1,800 shares Held by Martin D. Madaus 2011 Revocable Trust
RSU vesting date trigger May 14, 2027 or next annual meeting Earlier date controls vesting for RSUs and options
restricted stock units financial
"Mr. Madaus was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right to receive one share financial
"Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock."
Deferred Compensation Plan for Non-Employee Directors financial
"The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors."
separation of the Reporting Person's service as a Director financial
"shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Madaus Martin D
(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A995(1)A$0.006,581D
Common Stock1,800IBy Martin D. Madaus 2011 Revocable Trust
Common Stock11ISpouse Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$103.3805/14/2026A2,23905/14/2027(2)05/14/2036Common Stock2,239$0.002,239D
Explanation of Responses:
1. Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Jennifer Carmichael (Attorney in Fact)05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Repligen (RGEN) disclose in Martin D. Madaus’s latest Form 4?

Repligen reported equity awards to director Martin D. Madaus, not market trades. He received 995 restricted stock units and stock options on 2,239 shares, both vesting on the earlier of May 14, 2027 or the next annual shareholder meeting.

How many restricted stock units did Repligen (RGEN) grant to director Martin D. Madaus?

Repligen granted 995 restricted stock units to director Martin D. Madaus. Each unit represents a contingent right to receive one share of common stock, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting, subject to his continued service.

What are the terms of Martin D. Madaus’s new Repligen (RGEN) stock options?

Madaus received stock options covering 2,239 shares of Repligen common stock. The options have a $103.38 exercise price, vest in full on the earlier of May 14, 2027 or the next annual shareholder meeting, and expire on May 14, 2036 if not exercised.

How many Repligen (RGEN) shares does Martin D. Madaus hold after these equity grants?

After the reported awards, Madaus directly holds 6,581 Repligen common shares. He also indirectly holds 11 shares through a spouse trust and 1,800 shares through the Martin D. Madaus 2011 Revocable Trust, as disclosed in the Form 4 filing.

How are Martin D. Madaus’s Repligen (RGEN) restricted stock units settled?

The 995 restricted stock units may only be settled in Repligen common stock. Madaus elected to defer settlement under the Deferred Compensation Plan for Non-Employee Directors, so shares will be issued after his separation from board service, following his deferral election terms.

When do Martin D. Madaus’s Repligen (RGEN) equity awards vest?

Both the 995 restricted stock units and the 2,239-share stock option award vest in full on the earlier of May 14, 2027 or the date of the next annual shareholder meeting, which has not yet been determined, according to the Form 4 footnotes.